期刊文献+

内科胸腔镜对恶性胸腔积液的诊断和治疗 被引量:1

Medical thoracoscopy in the diagnosis and treatment of malignant pleural effusion
下载PDF
导出
摘要 目的探讨内科胸腔镜技术在恶性胸腔积液中诊断和治疗的临床应用。方法通过内科胸腔镜病理活检诊断为恶性胸腔积液,镜下进行滑石粉喷洒胸膜固定术,观察其疗效和并发症。结果 69例恶性胸腔积液病人被确诊,其中肺癌58例(腺癌41例、鳞癌8例、小细胞癌5例、腺鳞癌4例),胸膜间皮瘤3例,直(结)肠腺癌胸膜转移3例,乳腺癌2例,胸腺瘤1例,平滑肌肉瘤1例,淋巴细胞性淋巴瘤1例。诊断阳性率88.5%(69/78)。36例恶性胸腔积液患者行滑石粉喷洒胸膜固定术,有效率为91.7%(33/36),平均拔管时间为5.6 d(2~13 d)。主要并发症:胸痛29例(80.6%),发热16例(44.4%)。结论内科胸腔镜对恶性胸腔积液的诊断有重要价值,对恶性胸腔积液进行滑石粉喷洒胸膜固定术是一种安全、有效的治疗方法 。 Objective To study the clinical application of medical thoracoscopy to the diagnosis and treatment of malignant pleural effusions.Methods Medical thoracoscopy and pathological biopsy were used to diagnose the patients with malignant pleural effusions.Talc poudrage pleurodesis was performed under medical thoracoscopy and efficacy and complications of the treatment were evaluated.Results Of the 69 patients with malignant pleural effusions,58 were diagnosed as lung cancer(41 adenocarcinoma,8 squamous cel1 carcinoma,5 small cell carcinoma,4 adenosquamous cell carcinoma),3 mesothelioma,3 adenocarcinoma of colon and rectum,2 breast cancer,1 thymoma,1 leiomyosarcoma and 1 lymphocytic lymphoma.The diagnostic yield was 88.5%(69/78).Thirty-six patients with malignant pleural effusion underwent medical thoracoscopic talc poudrage pleurodesis.The average duration of thoracic tubing was 5.6(2-13) days.The total effective rate was 91.7%(33/36).The major complications were chest pain 80.6%(29/36) and fever 44.4%(16/36).Conclusion Medical thoracoscopy is an important diagnosis method for malignant pleural effusions,talc poudrage pleurodesis is a safe and effective treatment of malignant pleural effusions.
出处 《临床和实验医学杂志》 2010年第11期807-809,共3页 Journal of Clinical and Experimental Medicine
关键词 胸腔积液 胸腔镜 诊断 胸膜固定术 Pleural effusion Thoracoscopy Diagnosis Pleurodesis
  • 相关文献

参考文献13

  • 1Antony VB,Loddenkemper R,Astoul P,et al.Management of malignant pleural effusions[J].Eur Respir J,2001,18(2):402-419.
  • 2童朝辉,王臻,王辰.内科胸腔镜技术及其临床应用[J].中华结核和呼吸杂志,2007,30(3):220-222. 被引量:86
  • 3Antunes G,Neville E,Duffy J,et al.BTS guidelines for the management of malignant pleural effusions[J].Thorax,2003,58 (Suppl 2):1129-1138.
  • 4Khaleeq G,Musani AI.Emerging paradigms in the management of malignant pleural effusions[J].Respir Med,2008,102(7):939-948.
  • 5Chen H,Brahmer J.Management of malignant pleural effusion[J].Curr Oncol Rep,2008,10(4):287-293.
  • 6Heffner JE,Klein JS.Recent advances in the diagnosis and management of malignant pleural effusions[J].Mayo Clin Proc,2008,83(2):235-250.
  • 7Tan C,Sedrakyan A,Browne J,et al.The evidence on the effectiveness of management for malignant pleural effusion:a systematic review[J].Eur J Cardiothorac Surg,2006,29(5):829-838.
  • 8Shaw P,Agarwal R.Pleurodesis for malignant pleural effusions[J].Cochrane Database Syst Rev,2004,(1):CD002916.
  • 9Dresler CM,Olak J,Herndon JE 2nd,et al.Phase III intergroup study of talc poudrage vs.talc slurry sclerosis for malignant pleural effusion[J].Chest,2005,127(3):909-915.
  • 10de Campos JR,Vargas FS,de Campos Werebe E,et al.Thoracoscopy talc poudrage:a 15-year experience[J].Chest,2001,119(3):801-806.

二级参考文献40

共引文献92

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部